cryptocurrency t Top Knowledge

Since January 1, 2025, Chongqing maternity allowance has been issued to the insured female employees themselves. Recently, Chongqing Medical and Social Security Bureau issued the Notice on Adjusting the Payment Method for Maternity Insurance Benefits, and adjusted the payment method for maternity insurance benefits. From January 1, 2025, the application and method of maternity insurance benefits for the insured shall be applied by the insured himself or his client and issued to him by the medical insurance agency. In order to optimize the processing flow of maternity allowance, the service of "enjoy the maternity allowance immediately upon application" has been opened, that is, when the designated medical institutions in Chongqing settle the maternity medical expenses (delivery and termination of pregnancy), the medical insurance system automatically obtains the maternity-related information to calculate the maternity allowance, and the maternity allowance is paid to the insured after being approved by the medical insurance agency, and the insured or their clients do not need to provide relevant information to the medical insurance agency to declare the offline maternity allowance.For the first time, Nanjing Port docked with container ships of "longest ship scale" and "maximum load". Today (December 12th) morning, the largest container ship that entered the port since the opening of Nanjing Port, Panamanian vessel "Mai Di Hong Wei", successfully docked at Longtan Container Terminal, setting a new "double historical record" for the longest scale and maximum load of container ships entering the port. It is understood that the ship is 208.3 meters long, 29.8 meters wide and 33,715 tons deadweight. This voyage is a direct flight from Europe to Nanjing, which will directly increase the maximum container capacity of incoming ships from the current 1938TEU (standard container) to 2600TEU. The successful berthing indicates that 30,000-ton container ships can enter and leave Nanjing Port normally. (CCTV News)The Bank of Japan's short-term survey may show that business confidence has hardly changed. It is reported that the short-term survey released by the Bank of Japan on Friday may show that the mood of large manufacturers has remained almost unchanged in the last quarter under the influence of complex signals such as the recovery of the automobile industry and concerns about the global economic slowdown. Economists surveyed by data provider Quick predict that the prosperity judgment index of large-scale manufacturing industry will be +12, compared with +13 in the last survey. The survey is closely watched for clues about the decision of the Bank of Japan at its meeting next week. If it shows strong capital expenditure plan, high inflation expectation and tight employment situation, it may support the idea of raising interest rates early.

Market News: The Slovak Prime Minister said that Slovakia supports the normalization of relations between Russia and western countries and opposes the emergence of a new iron curtain in Europe. The Slovak Prime Minister emphasized that all conflicts will be finally resolved through negotiations.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)Huachuang Securities: It was first rated as "recommended" by Zangge Mining, with a target price of 33.3 yuan. Huachuang Securities Research Report pointed out that Zangge Mining (000408.SZ) is an important producer of potassium lithium salt and copper in China, with a high dividend return to shareholders. The company actively arranges high-quality potash resources at home and abroad: three major projects, namely, Heibei potash mine in Dalangtan, Alkali-Shishan potash mine and the eastern part of deep brine potash mine in Xiaoliangshan-Dafengshan area, are steadily promoted in China, with a total exploration right of 1,400 square kilometers; Overseas has signed a potash exploration agreement with Laos. At present, the exploration report and potash mine reserve certificate have been obtained. It is estimated that the total amount of potassium chloride resources in Setani County and Ba 'e County is 984 million tons. It is estimated that the output of the first phase of potassium chloride project will be 1 million tons/year, and the scale of potassium chloride production is expected to double in the future. The company is an important manufacturer of potassium and lithium in China, and Julong Copper is expected to inject strong kinetic energy into the company's growth. Considering that Mamicho Mining has not been consolidated at present, it is estimated that the company will realize a net profit of 25.0/27.7/4.29 billion yuan in 24-26 years, which is -27%, +11% and +54.9% respectively. In 2025, it can be compared with the company's average valuation of 19 times, giving the company a valuation of 19 times in 2025, corresponding to the target price of 33.3 yuan, covering for the first time and giving a "recommended" rating.

In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for the replacement of generic drugs. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)Zhongzhiwei Technology completed tens of millions of yuan financing. On December 12th, Nanjing Zhongzhiwei Information Technology Co., Ltd. (Zhongzhiwei Technology) completed tens of millions of yuan B1 financing, which was jointly invested by Guangzhou Baiyun Financial Holding Group Co., Ltd. and Beijing Hongfeng Private Equity Fund Management Co., Ltd. This round of financing funds will be used for iterative application of AI+ network security products, breakthrough in key industry landing scenarios and market channel construction. Zhongzhiwei Technology is a solution provider of "city-level data+digital security operation", and has launched a series of new platform-based network security products around AISecOps (artificial intelligence security operation).Aviation Materials Co., Ltd. released the Procurement Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd., and China Hangfa Online Mall released the Project of Feasibility Study Report of Beijing Aviation Materials Research Institute Co., Ltd.. The publishing unit is Beijing Institute of Aeronautical Materials Co., Ltd. (Aeronautical Materials Co., Ltd., 688563). Services include: feasibility study report of equity acquisition project; Feasibility study report on technology patent acquisition.